208 related articles for article (PubMed ID: 36701845)
21. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
Front Immunol; 2022; 13():918613. PubMed ID: 35874752
[TBL] [Abstract][Full Text] [Related]
22. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
[TBL] [Abstract][Full Text] [Related]
23. Erdheim-Chester disease: a case treated with IFN-α monitored using plasma and urine cell-free DNA.
Yang Z; Zhao S; Zhou J; Lei S; Hu Z
Immunotherapy; 2020 Apr; 12(6):379-387. PubMed ID: 32290742
[TBL] [Abstract][Full Text] [Related]
24. [Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].
Dasdelen S; Büschek F
Internist (Berl); 2020 Sep; 61(9):969-979. PubMed ID: 32785740
[TBL] [Abstract][Full Text] [Related]
25. Clinical presentation, imaging and response to interferon-alpha therapy in Erdheim-Chester disease: case-based review.
Iaremenko O; Petelytska L; Dyadyk O; Negria N; Fedkov D
Rheumatol Int; 2020 Sep; 40(9):1529-1536. PubMed ID: 32572610
[TBL] [Abstract][Full Text] [Related]
26. Erdheim-Chester Disease: a Concise Review.
Papo M; Emile JF; Maciel TT; Bay P; Baber A; Hermine O; Amoura Z; Haroche J
Curr Rheumatol Rep; 2019 Dec; 21(12):66. PubMed ID: 31807955
[TBL] [Abstract][Full Text] [Related]
27. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports.
Qiao J; Ma R; Peng X; He W
World J Surg Oncol; 2023 Jul; 21(1):233. PubMed ID: 37525276
[TBL] [Abstract][Full Text] [Related]
28. Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.
Mazor RD; Manevich-Mazor M; Kesler A; Aizenstein O; Eshed I; Jaffe R; Pessach Y; Goldberg I; Sprecher E; Yaish I; Gural A; Ganzel C; Shoenfeld Y
BMC Med; 2014 Dec; 12():221. PubMed ID: 25434739
[TBL] [Abstract][Full Text] [Related]
29. Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.
Salama H; Fahed Alzayed M; Alharbi KG; Khattak Z; Omer MH; Tahir L; ALhejazi A
Am J Case Rep; 2022 Feb; 23():e935090. PubMed ID: 35171900
[TBL] [Abstract][Full Text] [Related]
30. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
[TBL] [Abstract][Full Text] [Related]
31. Erdheim-Chester disease.
Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
[TBL] [Abstract][Full Text] [Related]
32. Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report.
Kim S; Lee M; Shin HJ; Lee J; Suh YL
Childs Nerv Syst; 2016 May; 32(5):893-6. PubMed ID: 26466952
[TBL] [Abstract][Full Text] [Related]
33. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
Haroche J; Abla O
Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha.
Braiteh F; Boxrud C; Esmaeli B; Kurzrock R
Blood; 2005 Nov; 106(9):2992-4. PubMed ID: 16020507
[TBL] [Abstract][Full Text] [Related]
35. Erdheim-Chester disease: expanding the spectrum of cutaneous manifestations.
Kobic A; Shah KK; Schmitt AR; Goyal G; Go RS; Guo R; Rech KL; Sartori-Valinotti JC;
Br J Dermatol; 2020 Feb; 182(2):405-409. PubMed ID: 31120137
[TBL] [Abstract][Full Text] [Related]
36. Clinical, laboratory and genetic features of Erdheim-Chester disease patients: analysis of a retrospective cohort of two reference centers in Latin America.
Guerra Soares Brandão AA; Ramires Neder Abdo A; Lage LAPC; Fatobene G; Pereira J; Rocha V
Hematology; 2022 Dec; 27(1):65-69. PubMed ID: 34957931
[No Abstract] [Full Text] [Related]
37. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
[TBL] [Abstract][Full Text] [Related]
38. Profound systemic alteration of the immune phenotype and an immunoglobulin switch in Erdheim-Chester disease in 78 patients from a single center.
Aubart FC; Poupel L; Saint-Charles F; Charlotte F; Arsafi Y; Frisdal E; Roos-Weil D; Emile JF; Amoura Z; Guerin M; Lesnik P; Haroche J; Le Goff W
Haematologica; 2022 Jun; 107(6):1347-1357. PubMed ID: 34647443
[TBL] [Abstract][Full Text] [Related]
39. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
[TBL] [Abstract][Full Text] [Related]
40. Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report.
Tamura S; Kawamoto K; Miyoshi H; Suzuki T; Katagiri T; Kasami T; Nemoto H; Miyakoshi S; Kobayashi H; Shibasaki Y; Masuko M; Takeuchi K; Ohshima K; Sone H; Takizawa J
J Clin Exp Hematop; 2018 Dec; 58(4):161-165. PubMed ID: 30305475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
